BioMarin Pharmaceutical Inc. (BMRN)

NMS – Real Time Price. Currency in USD

70.63

+1.08 (1.55%)

Market open: Aug 12, 2026, 2:49 PM EDT

69.60

+0.05 (0.07%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

12.08.2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

12.08.2026

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.

10.08.2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.

07.08.2026

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

07.08.2026

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

06.08.2026

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

06.08.2026

BioMarin Pharmaceutical Q2 Earnings Call Highlights

BioMarin Pharmaceutical NASDAQ: BMRN reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call.

Videos

No Data

There is no data to display

Press releases

10.08.2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

06.08.2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share (EPS) Addition of GALAFOLD® and POMBILITI® + OPFOLDA®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

BioMarin Pharmaceutical Inc. (BMRN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Q2 Earnings Call Highlights

Videos

No Data

Press releases

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BioMarin Reports Second Quarter 2026 Financial and Operating Results

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Q2 Earnings Call Highlights

Videos

No Data

Press releases

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Search stocks

BioMarin Pharmaceutical Inc. (BMRN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Q2 Earnings Call Highlights

Videos

No Data

Press releases

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BioMarin Reports Second Quarter 2026 Financial and Operating Results

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Q2 Earnings Call Highlights

Videos

No Data

Press releases

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BioMarin Reports Second Quarter 2026 Financial and Operating Results